IV iron dextran is most cost-effective, yielding 19.26 QALYs compared with 19.10 QALYs for oral ferrous sulfate.
New options for testing and treating some of the most common sexually transmitted diseases are becoming available.
Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback